Anti-HIV protease (HIV-1/HIV-2) Purified

Anti-HIV protease (HIV-1/HIV-2) Purified
Regulatory status
RUO
Antigen
HIV protease (HIV-1/HIV-2)
Clone
1696
Format
Purified
Reactivity
Human Immunodeficiency Virus
Application
ELISA, WB
Variant
0.1 mg
11-302-C100
In stock

0.025 mg
11-302-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
Images
References
Isotype
Mouse IgG1
Specificity
The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.
Application
ELISA, WB
Reactivity
Human Immunodeficiency Virus
Immunogen
Bacterially expressed full-length HIV-1 protease
Other names
HIV-1 PR, HIV-2 PR
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
11-302 DB
Dot blot analysis of recombinant HIV protease. The total amount of recombinant HIV-protease spotted on the nitrocellulose membrane are indicated in left column. Lane 1: anti-HIV protease (1696); 0.2 μg/ml Lane 2: anti-HIV protease (1696); 1.0 μg/ml Lane 3: anti-HIV protease (1696); 2.0 μg/ml

General references:

Kovalevsky AY, Chumanevich AA, Liu F, Louis JM, Weber IT: Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry. 2007 Dec 25;46(51):14854-64.
PubMed
Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg JE: Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics. 2008 Apr 10;9(1):181
PubMed
Brower ET, Bacha UM, Kawasaki Y, Freire E: Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008 Apr;71(4):298-305.
PubMed
Velazquez-Campoy A, Todd MJ, Vega S, Freire E: Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6062-7.
PubMed

Product specific references:

O'Loughlin TL, Greene DN, Matsumura I: Diversification and specialization of HIV protease function during in vitro evolution. Mol Biol Evol. 2006 Apr;23(4):764-72.
PubMed
Bartonová V, Král V, Sieglová I, Brynda J, Fábry M, Horejsí M, Kozísek M, Sasková KG, Konvalinka J, Sedlácek J, Rezácová P: Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 2008 Jun;78(3):275-7. Epub 2008 Feb 20.
PubMed
Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley GA: Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 1999 Dec;8(12):2686-96.
PubMed
Variant
0.1 mg
11-302-C100
In stock

0.025 mg
11-302-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock